[go: up one dir, main page]

RU2012158011A - METHOD AND COMPOSITION FOR TREATMENT OF CANCER - Google Patents

METHOD AND COMPOSITION FOR TREATMENT OF CANCER Download PDF

Info

Publication number
RU2012158011A
RU2012158011A RU2012158011/15A RU2012158011A RU2012158011A RU 2012158011 A RU2012158011 A RU 2012158011A RU 2012158011/15 A RU2012158011/15 A RU 2012158011/15A RU 2012158011 A RU2012158011 A RU 2012158011A RU 2012158011 A RU2012158011 A RU 2012158011A
Authority
RU
Russia
Prior art keywords
antivirulent
types
factors
cancer
treatment
Prior art date
Application number
RU2012158011/15A
Other languages
Russian (ru)
Inventor
Гриер Марк
Original Assignee
Николенко Сергей Андреевич
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Николенко Сергей Андреевич filed Critical Николенко Сергей Андреевич
Priority to RU2012158011/15A priority Critical patent/RU2012158011A/en
Publication of RU2012158011A publication Critical patent/RU2012158011A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Метод лечения или предупреждения рака, включающий в себя введение пациенту терапевтически эффективного количества одного или нескольких видов цитотоксических бактерий в комбинации с одним или несколькими видами антивирулентных факторов, где один или несколько антивирулентных факторов уменьшают или устраняют общую цитотоксичность одной или нескольких цитотоксических бактерий.A method of treating or preventing cancer, comprising administering to a patient a therapeutically effective amount of one or more types of cytotoxic bacteria in combination with one or more types of antivirulent factors, where one or more antivirulent factors reduce or eliminate the overall cytotoxicity of one or more cytotoxic bacteria.

Claims (1)

Метод лечения или предупреждения рака, включающий в себя введение пациенту терапевтически эффективного количества одного или нескольких видов цитотоксических бактерий в комбинации с одним или несколькими видами антивирулентных факторов, где один или несколько антивирулентных факторов уменьшают или устраняют общую цитотоксичность одной или нескольких цитотоксических бактерий.  A method of treating or preventing cancer, comprising administering to a patient a therapeutically effective amount of one or more types of cytotoxic bacteria in combination with one or more types of antivirulent factors, where one or more antivirulent factors reduce or eliminate the overall cytotoxicity of one or more cytotoxic bacteria.
RU2012158011/15A 2012-12-28 2012-12-28 METHOD AND COMPOSITION FOR TREATMENT OF CANCER RU2012158011A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2012158011/15A RU2012158011A (en) 2012-12-28 2012-12-28 METHOD AND COMPOSITION FOR TREATMENT OF CANCER

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2012158011/15A RU2012158011A (en) 2012-12-28 2012-12-28 METHOD AND COMPOSITION FOR TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
RU2012158011A true RU2012158011A (en) 2014-07-10

Family

ID=51215635

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012158011/15A RU2012158011A (en) 2012-12-28 2012-12-28 METHOD AND COMPOSITION FOR TREATMENT OF CANCER

Country Status (1)

Country Link
RU (1) RU2012158011A (en)

Similar Documents

Publication Publication Date Title
UA117451C2 (en) Therapeutically active compounds and their methods of use
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
WO2016106403A3 (en) Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
MX2013012253A (en) Novel binder-drug conjugates (adcs) and their use.
MX2017017138A (en) Targeted conjugates of ksp inhibitors.
TW201613578A (en) Pharmaceutical combinations
PH12016502352A1 (en) Pharmaceutical composition
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX367926B (en) Pharmaceutical composition for a sustained release of lanreotide.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer
TW201129361A (en) Methods for treating pain
MX2015005733A (en) Tricyclic compounds for use in the treatment and/or control of obesity.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2014014814A (en) Pharmaceutical composition for treating inflammation and pain.
MX2021014120A (en) Treatment of androgen deprivation therapy associated symptoms.
MX2017013666A (en) Anti-fugetactic agent and immunotherapy agent combination therapy and compositions for the treatment of cancer.
GB201115977D0 (en) Neurodevelopmental disorders
RU2012158011A (en) METHOD AND COMPOSITION FOR TREATMENT OF CANCER
EA201491836A1 (en) METHODS OF CANCER TREATMENT USING PI3K INHIBITOR AND MEK INHIBITOR
MX2021001081A (en) Combination therapy for treating cancer.
MX2018015240A (en) Compositions comprising timolol and their use in the treatment of rosacea by topical administration.
NZ631362A (en) Arry-520 for use in treating cancer in a patient with low aag